Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment
Authors:
- 1 November 2009
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 285 (1) , 58-65
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (2R01 CA88184, PC050769, PC074289)
- U.S. Department of War (2R01 CA88184, PC050769, PC074289)
This publication has 41 references indexed in Scilit:
- Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterolMolecular and Cellular Endocrinology, 2008
- Impact of gemcitabine on the treatment of metastatic pancreatic cancerJournal of Gastroenterology and Hepatology, 2005
- ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasionCancer Letters, 2004
- Simultaneously Targeting Epidermal Growth Factor Receptor Tyrosine Kinase and Cyclooxygenase-2, an Efficient Approach to Inhibition of Squamous Cell Carcinoma of the Head and NeckClinical Cancer Research, 2004
- ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cellsOncogene, 2003
- Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer modelsThe Prostate, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Akt, MAPK (Erk1/2), and p38 Act in Concert to Promote Apoptosis in Response to ErbB Receptor Family InhibitionJournal of Biological Chemistry, 2001
- Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cellsOncogene, 2000
- Bcl-2 and the regulation of programmed cell deathJournal of Cell Biology, 1994